Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of the Efficacy and Safety of Inhaled TQC3721 Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06527144 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of the Efficacy and Safety of Inhaled TQC3721 Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 14, 2024
- Completion date
- March 6, 2025
- Enrollment
- 240 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.